It is a medical ICT company established in 2014 and composed of excellent workforce, such as medical image AI specialists, global marketing specialists in the healthcare sector, medical professionals and advisors, etc. Aidot was discovering items targeting the global market in the early stages of its business. Aidot found an opportunity in applying IT to the medical field and started the medical ICT business in earnest.

As Aidot pursued its business, Aidot met many doctors who sympathized with the purpose of the business. Above all, Aidot felt great pride and delight in the fact that patients access to medical care increased and contribution is made to improve patients’ health as the service began to be used in actual medical fields.

Aidot has been developing artificial intelligence systems with support from government budgets. In recognition of its excellence by government agencies, Aidot received several awards, including the Minister of SMEs and Startups Award and the Minister of Science and Technology Award. In addition, Aidot was selected as one of K-Global 300 and promising export SME, and one of 100 national representative innovative companies.

Aidot has a corporate philosophy and sense of mission that the company’s achievements should be returned to society because the taxes of the people were used to grow Aidot. That’s why Aidot is proud that it is the only company in Korea that has a track record of exporting AI-based medical ICT systems.

Aidot is specialized in developing an artificial intelligence-based medical imaging system. The AI system for cervical cancer screening was supported by Software High Growth Club 200 and its commercialization has been already started. The development of the stroke screening system based on carotid artery ultrasound was completed, and clinical testing is under way in 4 university hospitals and medical device certification is in progress. Aidot also successfully developed systems related to all fields of internal medicine. Aidot installed endoscopy equipment for stomach, large intestine and small intestine at the gastroenterology department of Chuncheon Sacred Heart Hospital for clinical testing.

The AI system for remote cervical cancer diagnosis is called “Cerviray AI”. Cervical cancer and breast cancer are the most common cancers that threaten women’s health, and the cervical cancer is a serious disease with a fatality rate of 50%. Healthy women can prevent this disease with regular checkups once a year, but it is difficult for women in underdeveloped countries to undergo screening due to poor medical infrastructure, making it a major cause of death. The current main screening method, cervical cytology, requires the establishment of infrastructure such as laboratory facilities and pathologists. Therefore, this method has limitations in developing and underdeveloped countries.

Cerviray AI was developed for overseas markets with poor medical infrastructure such as China and Southeast Asia from the product planning stage, with the goal of contributing to the improvement of women’s health all over the world.

The global commercialization of the Cerviray product began in 2020. Aidot signed an exclusive distributor agreement with Snet in Beijing, China, and exported the first volume. Aidot also established a joint venture with a Shenzhen partner and are conducting aggressive sales activities. In addition, Aidot signed an exclusive distributor contract with CerviQ in the Philippines and are conducting local clinical testing. Aidot held a joint online event under the management of NIPA in May to commemorate the Month of Cervical Cancer Eradication.
To enter the Indonesian market, Aidot have established a joint system with domestic and local Indonesian conglomerates. Aidot plans to demonstrate Cervirary products and hold webinars for 1,000 doctors who are the members of the Indonesian Obstetrics and Gynecology Association. Aidot also have signed a contract or are discussing product introduction with partners in Thailand, Vietnam, Japan, and Paraguay.

Aidot received approval for the KFDA grade 3 clinical test for local use in Korea and entered the clinical testing stage and plans to conduct sales for a network of 3,000 hospitals in Korea, which was established by the joint venture partner Phil Medical Foundation from the first half of the year. Aidot is expected to become a really strong “small-but-strong” company based on leading ICT technology.

We were able to improve the perfection of Cerviray AI products, and as a result, we were able to successfully commercialize Cerviray AI. We have exported products through two partners in China since 2020 when we participated in the project. We’re making full-fledged overseas achievements such as tangible results in the Philippines and Indonesia. We received the grand prize of the Minister of Science and ICT in December 2020 in recognition of these achievements.

Researchers who have been silently devoted to R&D made all this possible. Also, the main effect was that the marketing budget was quickly changed to the online activity budget in preparation for the COVID-19 situation. We were fully prepared for online activities, such as the new production of high-quality product promotional videos and online brochures, and reorganization of the website into a multilingual version. Those activities were a great help.